This interview is part of our new AI in Healthcare series, where we interview the world's top thought leaders on the front lines of the intersections between AI and healthcare.
In this interview, we speak with Garri Zmudze, CEO of Longenesis, to understand how his company is using AI to transform healthcare, and what the future of the industry holds.
1. What’s the story behind Longenesis? Why and how did you begin?
GZ: It started in 2017 in a conversation with my friend Alex Zhavoronkov over a cup of tea, when we were discussing longevity and new technologies that are driving and improving the healthcare industry. We then started brainstorming how and where exactly blockchain can be integrated and used. That is when we came up with the idea of Longenesis. Next, we contacted my friends at Bitfury Group and started to build and develop what we have now.
2. Please describe your use case and how your company uses AI:
GZ: We use AI in our health risk calculators, which are used to calculate various health risks such as diabetes or hypertension predisposition. The patients receive reports regarding their specific risk.
3. Could you share a specific customer/user that benefits from what you offer? What has Longenesis done for them?
GZ: Our products focus on facilitating processes within healthcare organizations. Examples of what we do include improvement of consent management processes, provision of a completely effortless, paperless way for an organization to receive consent from patients for more effective onboarding for research and trials. This includes real-time management of the given consent, and a clear, auditable history log all based on a blockchain.
We take it even further in terms of patient onboarding and targeting, with the aid of our Dashboard — a search engine for pharmaceutical companies, and CROs (contract research organizations) that require datasets for their research and trials. The Dashboard uses anonymized metadata to give the searching parties a high-level overview to understand whether this is what they are looking for or not. They then make the request, create a call to action, and submit their fully compliant consent form. This is all provided in a white-labeled B2C interface that is easy and convenient to use. The AI tools are secondary.
4. What other AI use cases in healthcare are you excited about?
GZ: I believe that all the AI products and implementations created by Insilico Medicine are on the edge of a technological breakthrough. Alex Zhavoronkov's team is setting the pace for the industry. Insilico is developing tools that can trigger both AI advancement and the biology and chemistry efforts and is focusing on age-related diseases including sarcopenia, fibrosis, metabolic diseases, cancer and senescence in general. One of the platforms created by Insilico team, Pandomics.com, helps companies achieve their most challenging goals. Pandomics is a system available for target identification using multiple data types.
5. Where will your company be in five years?
GZ: I am certain that in five years we will redefine the life data economics market, and from there we will have two possibilities: either to stay independent and continue to expand and develop the business ourselves or to become a part of a larger corporation.